Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
about
PDCD5 says no to NO.Programmed cell death 5 suppresses AKT-mediated cytoprotection of endothelium.Co-targeting driver pathways in prostate cancer: two birds with one stone.Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.JMJD3 facilitates C/EBPβ-centered transcriptional program to exert oncorepressor activity in AML
P2860
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Targeting HDAC3, a new partner ...... kemia via DNA damage response.
@en
Targeting HDAC3, a new partner ...... kemia via DNA damage response.
@nl
type
label
Targeting HDAC3, a new partner ...... kemia via DNA damage response.
@en
Targeting HDAC3, a new partner ...... kemia via DNA damage response.
@nl
prefLabel
Targeting HDAC3, a new partner ...... kemia via DNA damage response.
@en
Targeting HDAC3, a new partner ...... kemia via DNA damage response.
@nl
P2093
P2860
P356
P1433
P1476
Targeting HDAC3, a new partner ...... kemia via DNA damage response.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2017.130
P577
2017-05-02T00:00:00Z